CClinicalTrials.gg
RecruitingNCT06822452PROSTAMBUUpdated Jul 8, 2025

Prospective Comparative Study Evaluating the Early Complications of Robot-assisted Radical Prostatectomy Performed as an Outpatient Versus an Inpatient Procedure.

An interventional study of radical prostatectomy in Prostate Cancer Surgery, Ambulatory Care and Outpatient Surgery, sponsored by Elsan. Recruiting at 12 sites in France. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-08.

Sponsored by Elsan · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
510
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

The goal of this clinical trial is to demonstrate that outpatient management for robotic-assisted radical prostatectomy is not inferior to inpatient management in terms of the occurrence of early post-operative complications.

Researchers will compare outpatient robot-assisted radical prostatectomy to inpatient procedure.

Participants will:

  • Visit the clinic after the operation once at 45 days, 6 months and once a year for up to 5 years for check-ups and tests.
  • Answer survey questions about urinary and erectil functions, stress and anxiety, satisfaction, quality of life for 6 months
  • Keep a diary to record procedures and treatments related to the care provided
02

Conditions studied

  • Prostate Cancer Surgery
  • Ambulatory Care
  • Outpatient Surgery
03

In context

Lead sponsor

Elsan is the lead sponsor of 66 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  • Male, aged 18 and over
  • Patient with prostate cancer for which the multidisciplinary meeting has proposed radical prostatectomy as a therapeutic option (with or without lymphadenectomy)
  • Patient eligible for outpatient treatment :

    1. The patient undertakes to comply with all medical instructions given during surgical consultations and the anaesthetic consultation.
    2. The patient has access to personal transport allowing, if necessary, return to the facility or another approved facility (transport time and distance from the facility are not exclusion factors)
    3. The patient has access to telephone communication facilities.
    4. The patient undertakes not to drive a vehicle and to be accompanied on his return home and for the next 24 hours by a responsible person who will be familiar with the monitoring instructions.
    5. The patient plans to remain in hospital overnight if this is deemed necessary by the department's doctors (operator and anaesthetist). The patient accepts this mode of care and its constraints.
  • Participant affiliated to or benefiting from a social security scheme
  • The participant has been informed and has given his/her free, informed and written consent (at the latest on the day of inclusion and before any examination required by the research).

Exclusion criteria

Exclusion Criteria:

  • Patient already treated for prostatic carcinoma with brachytherapy, radiotherapy or focal therapy
  • Patient participating in ongoing research or in a period of exclusion at the time of inclusion
  • Refusal or inability to comply with the study protocol for any reason whatsoever
  • Protected participant: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
510 participants (estimated)

Study arms

  • Experimental
    Outpatient procedure

    Procedure: radical prostatectomy

  • Active comparator
    Inpatient procedure

    Procedure: radical prostatectomy

Interventions

  • Procedureradical prostatectomy

    Robot-assisted

06

What researchers measure

Primary outcomes

  1. Early complication of robot-assisted prostatectomy

    The occurrence (yes/no) of at least one early complication of robot-assisted prostatectomy. The early clinical complications expected are : * Bleeding from trocar incision scars or surgical excision scars * Urinary leakage around the catheter * Retention due to bladder catheter clotting * Loss of bladder catheter * Signs of internal haemorrhage (within 24 hours) * Signs of biological deglobulation * Intestinal obstruction syndrome * Signs of urinary fistula * Infectious signs : fever \> 38°, chills * Thromboembolicaccidents * Nosocomial infections * Falls

    Time frame: From the day of surgery to 8 days post-operative

Secondary outcomes

  1. Conversion rate from outpatient to full hospitalisation (Outpatient failure rate)

    Patients treated on an outpatient basis for whom full hospitalisation is indicated on the day of surgery, as decided by the medical team.

    Time frame: Day of surgery

  2. Rate of cancellation of outpatient treatment by the patient or his private environment

    Patients included in the study refusing outpatient care up to the day of surgery (before or after surgery) for whatever reason

    Time frame: From enrollment to the day of surgery

  3. Rate of patients readmitted to hospital, either as emergencies or in the department

    Patients readmitted to hospital (yes/no), emergency or inpatient department

    Time frame: From hospital discharge to 8 days post-operative.

  4. Association of each early complication with treatment (outpatient or inpatient)

    Early complication of robot-assisted prostatectomy

    Time frame: From hospitalisation discharge to 8 days post-operative

  5. Rate of patients having had at least one complication secondary to surgery

    Patients who had at least one complication secondary to surgery. The expected complications secondary to surgery are: * Admission to emergency care * Re-hospitalization * Occlusions * Healing problems * Perineal hematoma * Urinary infections * Lymphoceles * Thromboembolic accidents * Nosocomial infections

    Time frame: From 8 days to 45 days post-operative

  6. Rate of patients with at least one complication secondary to surgery

    Patients who had at least one complication secondary to surgery.

    Time frame: From 45 days to 6 months post-operative

  7. Patient's pre-operative stress/anxiety levels

    The participant's stress/anxiety level is assessed at 3 days before surgery using the APAIS (Amsterdam Preoperative Anxiety and Information Scale) questionnaire validated in French (Moerman and al, 1996; Maurice-Szamburski and al, 2013), then with a Numerical Scale of stress/anxiety during preparation for the operating theatre in the care unit and at 2 days post-operative.

    Time frame: 3 days before surgery, day of surgery and 2 days post-operative

  8. Patient satisfaction level

    Patient satisfaction is assessed using the overall satisfaction question in the e-SATIS questionnaire ("Overall, how would you rate the quality of your treatment/care in the department by the doctors/surgeons/nurses? Bad/Weak/Average/Good/Excellent) The patient's opinion (yes/no) is evaluated on whether, if the procedure were repeated, the patient would accept it (yes/no) and whether it reassured him/her to go home in the evening /stay in hospital at night after the procedure.

    Time frame: 2 days and 45 days post-operative

  9. Duration of surgery

    Duration of surgery 'skin-to-skin' (incision until final stitch complete)

    Time frame: Day of surgery

  10. Blood loss

    The level of blood loss is assessed by the quantity of blood recovered in the aspiration jar and the quantity from the drains minus the quantity perfused intraoperatively in ml.

    Time frame: Day of surgery

  11. Rate of patients who recovered continence and rate of patients who recovered urinary function after surgery

    Urinary continence is assessed by the response to question 5 of the EPIC-50 (Expanded Prostate Cancer Index Composite) when 0 to 1 pads are used during the day by the patient. Recovery of urinary function was assessed by the difference between the incontinence subscore of the EPIC-50 questionnaire at D45 and the value of the pre-operative score. The incontinence subscore include questions 1, 3, 4, 5 and 6a of the urinary function EPIC-50 questionnaire. The EPIC-50 is a validated questionnaire (Wei and al, 2000) and translated into French (Anota and al, 2016).

    Time frame: Baseline and 45 days post-operative

  12. Evolution of urinary continence between 45 days and 6 months post-operatively and evolution of urinary function pre-operatively, at 45 days, at 6 months.

    The evolution of continence and urinary function is established on the basis of the parameters defined previously (see Secondary Outcome Measure 12.)

    Time frame: Baseline and 45 days, 6 months after surgery

  13. Recovery of erectile function

    Erectile recovery is assessed using the IIEF-5 (International Index of Erectile Function) questionnaire (Rosen R and al, 1997; Dargis and al, 2013) ; erectile dysfunction is defined by an IIEF-5 score \<10.

    Time frame: Baseline and 6 months post-operative

  14. Oncological recurrence and retreatment

    Recurrence is defined by a PSA (Prostate Specific Antigen) level \>0.1ng/ml, the patient's re-treatment (yes/no), the type of re-treatment (hormone therapy / chemotherapy / radiotherapy).

    Time frame: From 45 days to 5 years after surgery

  15. Economic and social cost of patient care

    The cost-utility ratio calculated on the basis of : \- The costs of the homogeneous group of patients (GHM) for hospitalisation and the costs of the national care reference system (ENCC) for post-operative management, based on the patient's diary completed up to 6 months after the operation. The following direct medical costs will be estimated from a societal perspective with a time horizon of 6 months: * Medical transport, medical and non-medical consultations in town, complementary examinations and drugs: collected in the CRF of the study from the patient logbook and valued using current tariffs. * The QALY, a unit for measuring life expectancy weighted by health-related quality of life, calculated on the basis of the utility derived from the EQ-5D-5L quality of life questionnaire completed by the patient at D0, D45 and 6 months after surgery.

    Time frame: From hospital discharge to 6 months post-operative

07

Study locations

7 of 12 sites recruiting
  • Clinique Rhône Durance
    Avignon, 84000, France
    Not yet recruiting
  • Clinique St Vincent
    Besançon, 25000, France
    Recruiting
  • Clinique St Augustin
    Bordeaux, 33074, France
    Recruiting
  • Polyclinique Médipôle St-Roch
    Cabestany, 66330, France
    Recruiting
  • Polyclinique du Parc
    Caen, 14000, France
    Not yet recruiting
  • Pole Sante Sud-CMCM
    Le Mans, 72100, France
    Recruiting
  • Hôpital Privé Nancy Lorraine
    Nancy, 54100, France
    Not yet recruiting
  • Polyclinique Les Fleurs
    Ollioules, 83190, France
    Recruiting
  • Polyclinique Santé Atlantique
    Saint-Herblain, 44800, France
    Not yet recruiting
  • Clinique Belledonne
    Saint-Martin-d'Hères, 38400, France
    Recruiting
  • Centre clinical
    Soyaux, 16800, France
    Not yet recruiting
  • Hôpital Privé Océane
    Vannes, 56000, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06822452
Lead sponsor
Elsan
Responsible party
Sponsor
First posted
Feb 12, 2025
Start date
Dec 30, 2024
Primary completion
Jan 7, 2027 (estimated)
Completion
Apr 30, 2030 (estimated)
Last update
Jul 8, 2025

Study contacts

Charlène PY, Eng
Contact
charlene.py@elsan.care
+33556003048

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion